Algernon Pharmaceuticals (XTER:BTI) Net Income From Continuing Operations : €-3.53 Mil (TTM As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Algernon Pharmaceuticals's net income from continuing operations for the three months ended in Feb. 2024 was €-0.69 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Feb. 2024 was €-3.53 Mil.

Algernon Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Algernon Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Net Income From Continuing Operations Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-1.28

-5.45

-5.22

-4.63

-4.61

Algernon Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.87	-0.77	-1.72	-0.35	-0.69

Algernon Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.53 Mil.

Algernon Pharmaceuticals (XTER:BTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XTER:BTI) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.